Kiser Andy C, O'Neill William W, de Marchena Eduardo, Stack Richard, Zarate Mauricio, Dager Antonio, Reardon Michael
University of North Carolina, Chapel Hill, NC, USA
Henry Ford Hospital, Detroit, MI, USA.
Eur J Cardiothorac Surg. 2015 Nov;48(5):778-83; discussion 784. doi: 10.1093/ejcts/ezu524. Epub 2015 Jan 18.
Direct aortic deployment of a transcatheter aortic valve eliminates the need to traverse the aortic arch with the valve delivery system, enables placement of large sheaths in the aorta and innominate artery, provides maximal precision during deployment and ensures a safe, conventional surgical aortotomy closure. We describe the initial experience with the Suprasternal Aortic Access System (SuprAA System, Aegis Surgical Ltd, Dublin, Ireland) for direct transaortic/innominate valve delivery.
Patients with severe, symptomatic aortic stenosis who were candidates for transcatheter aortic valve replacement (TAVR) via a direct transaortic approach were enrolled in the SuprAA-TAVR First-in-Man Study. Under general anaesthesia, the innominate artery and aortic arch were exposed in each patient, using the SuprAA System via a 2.5-cm incision directly above the sternal notch. The TAVR delivery sheath was positioned and the transcatheter valve deployed routinely under fluoroscopic guidance. Upon sheath removal, haemostasis at the aortotomy site was confidently secured using a double purse-string suture closure. All were extubated immediately. A meta-analysis of the direct aortic approach was done for comparison.
Four male patients (mean 82.5 years) underwent SuprAA-TAVR (2 CoreValve; 2 SAPIEN). Anatomical visualization was excellent and suprasternal valve deployment was accurate regardless of sheath size with 100% Valve Academic Research Consortium-2 procedural success. The average total procedure time was 109.5 min without perioperative wound or vascular complications.
The SuprAA System provides direct aortic/innominate access without sternal or thoracotomy incision. Patient recovery to normal activity is maximized, sheath size limitations are eliminated and valve deployment is precise. This innovative system creates a new and exciting minimally invasive approach for high-risk patients with aortic stenosis.
经导管主动脉瓣直接在主动脉内展开,无需使用瓣膜输送系统穿过主动脉弓,可在主动脉和无名动脉中放置大鞘管,在展开过程中提供最大精度,并确保安全、常规的手术主动脉切开术闭合。我们描述了使用胸骨上主动脉接入系统(SuprAA系统,爱尔兰都柏林的宙斯盾外科有限公司)进行经主动脉/无名动脉瓣膜直接输送的初步经验。
经直接经主动脉途径进行经导管主动脉瓣置换术(TAVR)的重度症状性主动脉瓣狭窄患者被纳入SuprAA-TAVR人体首例研究。在全身麻醉下,通过胸骨切迹上方2.5厘米的切口,使用SuprAA系统暴露每位患者的无名动脉和主动脉弓。定位TAVR输送鞘管,并在荧光透视引导下常规展开经导管瓣膜。拔除鞘管后,使用双荷包缝线闭合可靠地确保主动脉切开部位止血。所有患者均立即拔管。对直接主动脉途径进行荟萃分析以作比较。
4名男性患者(平均82.5岁)接受了SuprAA-TAVR(2枚CoreValve;2枚SAPIEN)。解剖结构可视化良好,无论鞘管大小,胸骨上瓣膜展开均准确无误,瓣膜学术研究联盟-2程序成功率达100%。平均总手术时间为109.5分钟,无围手术期伤口或血管并发症。
SuprAA系统提供直接的主动脉/无名动脉接入,无需胸骨切开或开胸切口。患者恢复正常活动的程度最大化,消除了鞘管大小限制,瓣膜展开精确。这一创新系统为高危主动脉瓣狭窄患者开创了一种全新且令人兴奋的微创方法。